Search

1585 Background: Two types of adipose tissue exist: white adipose tissue (WAT) and BAT. WAT is the main energy store in humans and is associated with obesity and inflammation. BAT is thought to be protective against obesity and acts as an energy dissipating organ, which may fight obesity by reducing adipokines, inflammatory cytokines, and insulin resistance. The relationship of brown fat activation and cancer prognosis is unknown. We hypothesize that BAT may be protective to breast cancer patients by shifting glucose pool away from tumors and reducing tumor activity. Methods: Through a retrospective chart review of over 900 patients treated by the Breast Cancer Group at our institution, we identified 98 patients with BAT on PET CT scans. We collected information on patient demographics, lifestyle, staging and treatments received and response, progression of disease, overall survival, labs (lipids, hemoglobin A1C, Vitamin D, CRP), metabolic syndrome, metformin use, and antidepressants. Results: Of the 98 c...

e16001 Background: Cetuximab (Cx) + radiation therapy (RT) is well tolerated and has improved survival in patients (pts) with LA-HNSCC. However, its efficacy when compared to HD-DDP + RT has been questioned. At our institution, low-dose weekly carboplatin (Carbo) is added to Cx + RT for pts unsuitable for HD-DDP. Methods: We reviewed records of 16 pts with LA-HNSCC treated with definitive Cx + Carbo + RT at the University of Miami from 2007-2011. Median follow-up was 9.4 months (range: 1-50 months). Results: Median age: 71.5 years (range: 57-90 years); 15 male, 1 female.ECOG PS 0=15, 1=1. TNM staging was: T1= 1, T2= 5, T3=8, T4=2; N stage: N0=8, N1=5, N2a=2, N2b=1. All pts received weekly Carbo (AUC 1.5-2), Cx given conventionally and daily conventionally-fractionated RT. Median total weeks of concurrent systemic therapy= 7 (range: 3-8 weeks). RT was delivered to a median total dose of 70 Gy (range 30-74 Gy). Of the 15 evaluable pts, there were: 12 CR, 2 PR, and 1 PD. There were 2 local in-field failures, 1 regional failure, and 3 distant failures. At last follow-up, 11/16 pts remained with NED. 3-year locoregional recurrence was 29.5% (95% CI: 5.3%-45.9%). Toxicity (NCI-CTCAE v4.0): Mean percentage of weight loss was 14% (range: 6-26%). Two pts required systemic therapy dose-reduction. Three pts experienced a treatment delay and 3 did not finish RT as planned including one pt who received only 30Gy due to death secondary to MI during treatment. Conclusions: In this small retrospective series, Carbo/Cx/RT was well-tolerated and efficacious in pts unsuitable for HD-DDP having LA-HNSCC. Acute toxicities were similar to Cx + RT, likely due to the non-overlapping toxicity profiles of the two systemic agents. We hypothesize that the addition of a well-tolerated cytotoxic chemotherapy agent may improve the therapeutic ratio of Cx + RT in pts who are poor candidates for more aggressive therapies and warrants evaluation in a prospective manner. [Table: see text]

e18562 Background: BDM is approved in the United States for relapsed indolent lymphoma. However, the prospective study establishing the BDM monotherapy indication did not include any MCL pts (Fried...